{'fraction_non_alphanumeric': 0.03287671232876712, 'fraction_numerical': 0.03561643835616438, 'mean_word_length': 5.356521739130435, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 1, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
How effective is omalizumab as a second-line treatment for chronic urticaria in patients who do not respond to antihistamines?

After failing first-line therapy with a secondgeneration antihistamine up to four times the normal dose, the use of omalizumab is themost effective second-line treatment and can have a complete response as measured by itch severity scores reported by patients (SOR: A, meta-analysis of randomized controlled trials [RCTs]). The addition of omalizumab to antihistamine treatment regimens can reduce the symptoms of urticaria and increase the number of patients achieving complete relief (SOR: B, single RCT). Copyright © 2020 by Family Physicians Inquiries Network, Inc. DOI 10.1097/EBP.0000000000001078